Biological Sciences Division, Pacific Northwest National Laboratory, Washington, USA.
Cancer Biomark. 2010;8(4-5):223-30. doi: 10.3233/CBM-2011-0216.
The stark difference in clinical outcome for patients with ovarian cancer diagnosed at early stages (95% survival at 5 years) versus late stages (27.6% survival at 5 years) has driven a decades-long quest for effective biomarkers that will enable earlier detection of ovarian cancer. Yet despite intense efforts, including the application of modern high throughput technologies including transcriptomics and proteomics, there has been little improvement in performance compared to the gold standard of quantifying serum CA125 immunoreactivity paired with transvaginal ultrasound. This review describes the strategies that have been used for identification of ovarian cancer biomarkers, including the recent introduction of novel bioinformatic approaches. Results obtained using high throughput-based vs. biologically rational approaches for the discovery of diagnostic early detection biomarkers are compared and analyzed for functional enrichment.
早期诊断的卵巢癌患者（5 年生存率为 95%）与晚期诊断的患者（5 年生存率为 27.6%）在临床结果上存在明显差异，这促使人们数十年来一直在寻找有效的生物标志物，以实现卵巢癌的早期检测。然而，尽管进行了大量努力，包括应用现代高通量技术，如转录组学和蛋白质组学，与定量检测血清 CA125 免疫反应性并结合经阴道超声检查的金标准相比，其性能几乎没有改善。本综述描述了用于鉴定卵巢癌生物标志物的策略，包括最近引入的新型生物信息学方法。比较并分析了基于高通量与基于生物学合理性的方法在发现诊断性早期检测生物标志物方面的结果，以进行功能富集分析。
